CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

176 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BPIK3CAMutation OR RB1 Mutation OR ESR1 MutationPredictiveSupportsResistanceBreast CancerPalbociclib,FulvestrantO'Leary et al., 2018
APIK3CAH1047R OR PIK3CA H1047Y OR PIK3CA H1047L OR PIK3CA H1047D OR PIK3CA H1047I OR PIK3CA H1047N OR PIK3CA H1047P OR PIK3CA H1047Q OR PIK3CA H1047TPredictiveSupportsSensitivity/ResponseBreast CancerFulvestrant,Inavolisib,PalbociclibWedam et al., 2025
APIK3CAE545K OR PIK3CA E545Q OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545V OR PIK3CA E545D OR PIK3CA E545L OR PIK3CA E545RPredictiveSupportsSensitivity/ResponseBreast CancerFulvestrant,Palbociclib,InavolisibWedam et al., 2025
APIK3CAE542K OR PIK3CA E542Q OR PIK3CA E542A OR PIK3CA E542D OR PIK3CA E542G OR PIK3CA E542R OR PIK3CA E542VPredictiveSupportsSensitivity/ResponseBreast CancerInavolisib,Fulvestrant,PalbociclibWedam et al., 2025
APIK3CAQ546K OR PIK3CA Q546E OR PIK3CA Q546P OR PIK3CA Q546R OR PIK3CA Q546L OR PIK3CA K111E OR PIK3CA K111N OR PIK3CA K111R OR PIK3CA Q546HPredictiveSupportsSensitivity/ResponseBreast CancerInavolisib,Fulvestrant,PalbociclibWedam et al., 2025
APIK3CAG1049S OR PIK3CA G1049R OR PIK3CA G106V OR PIK3CA G106R OR PIK3CA G1049A OR PIK3CA G106S OR PIK3CA G106A OR PIK3CA G106D OR PIK3CA G118D OR PIK3CA G1049C OR PIK3CA G1049DPredictiveSupportsSensitivity/ResponseBreast CancerFulvestrant,Inavolisib,PalbociclibWedam et al., 2025
APIK3CAN345K OR PIK3CA N345D OR PIK3CA N345H OR PIK3CA N345I OR PIK3CA N345S OR PIK3CA N345T OR PIK3CA N345YPredictiveSupportsSensitivity/ResponseBreast CancerFulvestrant,Palbociclib,InavolisibWedam et al., 2025
APIK3CAR88Q OR PIK3CA C420R OR PIK3CA M1043V OR PIK3CA M1043I OR PIK3CA M1043TPredictiveSupportsSensitivity/ResponseBreast CancerFulvestrant,Inavolisib,PalbociclibWedam et al., 2025
APIK3CAE453K OR PIK3CA E453Q OR PIK3CA E453A OR PIK3CA E453D OR PIK3CA E453G OR PIK3CA E453VPredictiveSupportsSensitivity/ResponseBreast CancerInavolisib,Fulvestrant,PalbociclibWedam et al., 2025
BPIK3CAExon 21 Mutation AND PIK3CA Exon 10 MutationPredictiveSupportsSensitivity/ResponseColorectal CancerAspirinMartling et al., 2025
BPIK3CAH1047RPredictiveDoes Not SupportResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
BPIK3CAExon 10 MutationPrognosticDoes Not SupportPoor OutcomeColorectal CancerLiao et al., 2012
CPIK3CAH1047RPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
CPIK3CAAmplificationPredictiveSupportsSensitivity/ResponseEpithelial Ovarian CancerPictilisibSarker et al., 2015
DPIK3CAE545KPredictiveSupportsResistanceLung AdenocarcinomaGefitinibEngelman et al., 2006
DPIK3CAMutationPredictiveDoes Not SupportSensitivity/ResponseCancerTanespimycin,PictilisibWirtz et al., 2015
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHead And Neck CancerDactolisibLui et al., 2013
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHead And Neck CancerCetuximab,DactolisibLui et al., 2013
DPIK3CAMutationPredictiveDoes Not SupportSensitivity/ResponseHead And Neck CancerPictilisib,Tanespimycin,TrametinibWirtz et al., 2015
BPIK3CAMutationPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabBerns et al., 2007
DPIK3CAE545KPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabSerra et al., 2008
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaTaselisibZumsteg et al., 2016
DPIK3CAMutationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerCapivasertibDavies et al., 2012
CPIK3CAE542KPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaApitolisibDolly et al., 2016
CPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerEverolimus,FulvestrantSun et al., 2016
CPIK3CAE545KPredictiveSupportsResistanceLung AdenocarcinomaErlotinib,GefitinibBelchis et al., 2016
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPictilisibO'Brien et al., 2010
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
DPIK3CAE545KPredictiveSupportsSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
CPIK3CAE545KPredictiveDoes Not SupportResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
DPIK3CAE545KPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPI103Zou et al., 2009
BPIK3CARare MutationPrognosticSupportsBetter OutcomeBreast CancerKalinsky et al., 2009
BPIK3CAH1047RPrognosticSupportsBetter OutcomeBreast CancerKalinsky et al., 2009
BPIK3CAH1047RPrognosticSupportsBetter OutcomeBreast CancerMaruyama et al., 2007
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
BPIK3CAE545KPrognosticSupportsPoor OutcomeRectum CancerHe et al., 2009
CPIK3CAQ546KPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,IrinotecanDe Roock et al., 2010
DPIK3CAE545KPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
DPIK3CAE545GPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
BPIK3CAExon 21 MutationPrognosticDoes Not SupportPoor OutcomeColorectal CancerLiao et al., 2012
BPIK3CAMutationPredictiveDoes Not SupportResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
CPIK3CAE81KPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,Fluorouracil,OxaliplatinDe Roock et al., 2010
CPIK3CAR93WPredictiveSupportsResistanceColorectal CancerFluorouracil,Oxaliplatin,CetuximabDe Roock et al., 2010
DPIK3CAD350GPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
BPIK3CAExon 21 Mutation AND PIK3CA Exon 10 MutationPrognosticSupportsPoor OutcomeColorectal CancerLiao et al., 2012
DPIK3CAK111NPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab,Dactolisib,LapatinibEichhorn et al., 2008
DPIK3CAAmplificationPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabEichhorn et al., 2008
DPIK3CAAmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerLapatinib,DactolisibEichhorn et al., 2008
DPIK3CAE545KPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabBaselga et al., 2016
DPIK3CAH1047RPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabBaselga et al., 2016
Page 3 of 4
PreviousNext